TR200000145T2 - Kemik erimesini durdurmak için bir yöntem - Google Patents

Kemik erimesini durdurmak için bir yöntem

Info

Publication number
TR200000145T2
TR200000145T2 TR2000/00145T TR200000145T TR200000145T2 TR 200000145 T2 TR200000145 T2 TR 200000145T2 TR 2000/00145 T TR2000/00145 T TR 2000/00145T TR 200000145 T TR200000145 T TR 200000145T TR 200000145 T2 TR200000145 T2 TR 200000145T2
Authority
TR
Turkey
Prior art keywords
bone resorption
clodronate
methods
stop bone
stop
Prior art date
Application number
TR2000/00145T
Other languages
English (en)
Turkish (tr)
Inventor
G. Daifotis Anastasia
C. Santora Ii Arthur
John Yates A.
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000145(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of TR200000145T2 publication Critical patent/TR200000145T2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
TR2000/00145T 1997-07-22 1998-07-17 Kemik erimesini durdurmak için bir yöntem TR200000145T2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Publications (1)

Publication Number Publication Date
TR200000145T2 true TR200000145T2 (tr) 2000-05-22

Family

ID=27451690

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00145T TR200000145T2 (tr) 1997-07-22 1998-07-17 Kemik erimesini durdurmak için bir yöntem

Country Status (31)

Country Link
EP (5) EP1132088A3 (cg-RX-API-DMAC7.html)
JP (2) JP3479780B2 (cg-RX-API-DMAC7.html)
KR (3) KR20030097610A (cg-RX-API-DMAC7.html)
CN (3) CN1299689C (cg-RX-API-DMAC7.html)
AT (2) ATE209037T1 (cg-RX-API-DMAC7.html)
AU (1) AU8493698A (cg-RX-API-DMAC7.html)
BG (1) BG66282B1 (cg-RX-API-DMAC7.html)
BR (1) BR9810779A (cg-RX-API-DMAC7.html)
CA (1) CA2294595C (cg-RX-API-DMAC7.html)
CY (2) CY1107535T1 (cg-RX-API-DMAC7.html)
DE (6) DE122007000063I1 (cg-RX-API-DMAC7.html)
DK (2) DK0998292T3 (cg-RX-API-DMAC7.html)
EA (1) EA004544B2 (cg-RX-API-DMAC7.html)
EE (1) EE05603B1 (cg-RX-API-DMAC7.html)
ES (3) ES2164447T3 (cg-RX-API-DMAC7.html)
HK (4) HK1042230A1 (cg-RX-API-DMAC7.html)
ID (1) ID24096A (cg-RX-API-DMAC7.html)
IL (1) IL133535A0 (cg-RX-API-DMAC7.html)
IS (3) IS5315A (cg-RX-API-DMAC7.html)
LU (2) LU91222I2 (cg-RX-API-DMAC7.html)
NL (2) NL300223I1 (cg-RX-API-DMAC7.html)
NO (1) NO20000323L (cg-RX-API-DMAC7.html)
NZ (1) NZ501807A (cg-RX-API-DMAC7.html)
PL (1) PL195272B1 (cg-RX-API-DMAC7.html)
PT (2) PT998292E (cg-RX-API-DMAC7.html)
SG (2) SG139556A1 (cg-RX-API-DMAC7.html)
SI (1) SI0998292T1 (cg-RX-API-DMAC7.html)
SK (1) SK932000A3 (cg-RX-API-DMAC7.html)
TR (1) TR200000145T2 (cg-RX-API-DMAC7.html)
UY (1) UY25950A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999004773A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1147773B1 (en) * 1998-12-25 2004-04-07 Yamanouchi Pharmaceutical Co. Ltd. Medicinal compositions for treating osseous lesion in multiple myeloma
PL351674A1 (en) * 1999-05-21 2003-05-19 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
US6670343B1 (en) * 1999-07-19 2003-12-30 Toray Industries, Inc. Drugs for periodontal disease
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
WO2001046040A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Blister package for pharmaceutical treatment card
CN1446093A (zh) * 2000-04-07 2003-10-01 得克萨斯系统大学董事会 两性离子型磷脂和双膦酸酯的独特组合物及其作为降低肠胃毒性的双膦酸酯释放系统的应用
DK1591122T3 (da) * 2000-06-20 2013-02-25 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
NZ523086A (en) 2000-06-20 2007-07-27 Novartis Ag Method of administering bisphosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
EP1392325B1 (en) * 2001-05-02 2006-06-21 Novartis AG Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis
KR20150053811A (ko) * 2002-05-10 2015-05-18 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
CN1852719A (zh) * 2003-09-19 2006-10-25 辉瑞产品公司 包括2-亚烷基-19-去甲-维生素d衍生物和二膦酸盐的组合的药物组合物和方法
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
NZ567200A (en) * 2005-09-16 2010-08-27 Selamine Ltd Bisphosphonate formulation
CN103140220A (zh) * 2010-12-06 2013-06-05 给药技术公司 具有快速溶解特性的稳定的泡腾双磷酸盐制剂
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
DK0521388T3 (da) * 1991-07-01 1995-09-11 Gergely Gerhard Fremgangsmåde til fremstilling af et farmaceutisk præparat med mindst to forskellige aktivstoffer samt anvendelsen af et sådant præparat
WO1993009785A1 (en) * 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
DK0648120T3 (da) * 1992-06-30 1998-01-19 Procter & Gamble Pharma Anvendelse af phosphonater til behandling af osteoporose
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
JPH11506750A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 慢性関節リウマチに係わる骨欠損に対するビスホスホネート療法
JP2000511178A (ja) * 1996-05-17 2000-08-29 メルク エンド カンパニー インコーポレーテッド 発泡性ビスホスホネート製剤

Also Published As

Publication number Publication date
HK1040495A1 (en) 2002-06-14
DK0998292T3 (da) 2002-05-13
DE69837450T2 (de) 2007-08-23
IL133535A0 (en) 2001-04-30
HK1024166A1 (en) 2000-10-05
SI0998292T1 (en) 2002-04-30
LU91222I2 (fr) 2006-04-18
PT1175904E (pt) 2007-04-30
KR100391732B1 (ko) 2003-07-16
ID24096A (id) 2000-07-06
DE01201913T1 (de) 2007-02-08
BR9810779A (pt) 2000-07-25
BG104093A (en) 2000-10-31
EP1151752A2 (en) 2001-11-07
WO1999004773A2 (en) 1999-02-04
HK1042230A1 (en) 2002-08-09
EP1175904B1 (en) 2007-03-28
UY25950A1 (es) 2000-09-29
NL300223I1 (nl) 2006-04-03
JP3479780B2 (ja) 2003-12-15
DE69803291T2 (de) 2002-08-08
IS5315A (is) 1999-12-21
BG66282B1 (bg) 2013-01-31
CN1602879A (zh) 2005-04-06
LU91364I2 (fr) 2007-11-12
HK1042232A1 (en) 2002-08-09
EP1175903A2 (en) 2002-01-30
NL300292I1 (nl) 2007-11-01
ES2269014T3 (es) 2007-05-01
CA2294595C (en) 2001-08-21
PL195272B1 (pl) 2007-08-31
KR20030097611A (ko) 2003-12-31
CN1265035A (zh) 2000-08-30
EP1132088A2 (en) 2001-09-12
SK932000A3 (en) 2000-09-12
EE200000040A (et) 2000-10-16
DK1175904T3 (da) 2007-05-07
WO1999004773A3 (en) 1999-04-15
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
CN1166365C (zh) 2004-09-15
ES2269014T1 (es) 2007-04-01
WO1999004773A9 (en) 1999-10-28
ATE357921T1 (de) 2007-04-15
EP0998292B1 (en) 2001-11-21
CN1299689C (zh) 2007-02-14
CA2294595A1 (en) 1999-02-04
EP1132088A3 (en) 2002-04-24
EP1175903A3 (en) 2002-12-18
JP2005068010A (ja) 2005-03-17
NO20000323L (no) 2000-03-20
EA004544B1 (ru) 2004-06-24
IS7231A (is) 2004-04-21
EA004544B2 (ru) 2006-12-29
PT998292E (pt) 2002-04-29
AU8493698A (en) 1999-02-16
CY2007022I2 (el) 2012-01-25
KR20010022110A (ko) 2001-03-15
DE122007000063I1 (de) 2007-12-20
HK1040494A1 (en) 2002-06-14
EP1151752A3 (en) 2002-12-18
EP1175904A3 (en) 2002-12-18
DE69837450D1 (de) 2007-05-10
PL338635A1 (en) 2000-11-06
CN1602880A (zh) 2005-04-06
JP2002502433A (ja) 2002-01-22
DE01201911T1 (de) 2007-10-18
ATE209037T1 (de) 2001-12-15
IS7230A (is) 2004-04-21
NZ501807A (en) 2003-02-28
EP1175904B8 (en) 2007-05-09
EP0998292A2 (en) 2000-05-10
DE122006000009I1 (de) 2006-06-14
CY2007022I1 (el) 2012-01-25
EE05603B1 (et) 2012-12-17
EA200000151A1 (ru) 2000-10-30
EP1175904A2 (en) 2002-01-30
ES2253136T1 (es) 2006-06-01
SG109478A1 (en) 2005-03-30
CY1107535T1 (el) 2012-01-25
KR20030097610A (ko) 2003-12-31
DE69803291D1 (de) 2002-02-21
ES2164447T3 (es) 2002-02-16

Similar Documents

Publication Publication Date Title
TR200000145T2 (tr) Kemik erimesini durdurmak için bir yöntem
NZ527157A (en) Compositions for delivering bisphosphonates
NZ272608A (en) Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
NZ545804A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
EP1178810B8 (en) Use of bisphosphonic acids for treating angiogenesis
BR0309691A (pt) Formulação de ibandronato em alta dose
TR200805763T2 (tr) Kemik erimesini durdurmak için bir yöntem
BR9609477A (pt) Composto composição farmacêutica e processos para preparação de tiludronato dissódico e para obtenção de uma composição farmacêutica
MX9709906A (es) Uso de bisfosfonatos para preparar composiciones para prevenir perdida de hueso asociada con terapia inmunosupresora.
TWI226833B (en) Pharmaceutical composition for inhibiting bone resorption